Zambon, a Bresso, Italy-headquartered pharmaceutical company focused on central nervous system (CNS) therapeutics, has entered into a strategic agreement with Valeo Pharma, a Montreal, Canada-headquartered specialty pharmaceutical company, to commercialize Xadago (safinamide), a Parkinson’s disease drug, in Canada.

Under the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada. Valeo Pharma will pay Zambon upfront, regulatory, and commercial milestone payments as well as royalties on product sales.

Zambon has launched Xadago in Germany, Switzerland, Spain, Italy, Belgium, Denmark, Sweden, UK, Luxembourg, the Netherlands, and Norway and holds the global marketing rights for safinamide, except in Japan and Asia, where Meiji Seika Pharma, a Tokyo-headquartered pharmaceutical company, has the rights to develop and commercialize the compound. Zambon granted the rights to commercialize Xadago in the US to US WorldMeds, a Louisville, Kentucky-based specialty pharmaceutical company.

Source: Valeo Pharma